JPET #82768 4 Nociceptin/Orphanin FQ (N/OFQ), an opioid-like peptide containing 17 amino acids, is the endogenous ligand for the N/OFQ peptide receptor (NOP, also referred to as ORL1 ; Meunier et al., 1995; Reinscheid et al., 1995; Cox et al., 2000) . N/OFQ has a high degree of structural similarity to that of endogenous opioid peptides with particular resemblance to dynorphin A(1-17), the native kappa opioid peptide (KOP) receptor ligand (Civelli et al., 1997) . Despite sequence similarity, N/OFQ has no appreciable affinity for classical opioid receptors and instead selectively activates its own NOP receptors . Upon activating NOP receptors N/OFQ modulates second messenger pathways via G i/o to alter neurotransmitter and hormonal release and elicit organ responses at central and peripheral levels (Hawes et al., 2000) . N/OFQ produces marked changes in cardiovascular and renal function in conscious or anesthetized rats (Kapusta, 2000; Salis et al., 2000; Malinowska et al., 2002) . In this regard, intracerebroventricular (i.c.v.) injection of N/OFQ produces a dose-dependent bradycardia, hypotension, diuresis and antinatriuresis Kapusta et al., 1997; Shirasaka et al., 1999) . The cardiovascular depressor responses elicited by central N/OFQ occur shortly after administration (15 sec-1 min) and are prolonged in duration (30-40 min) .
Central N/OFQ also evokes a concurrent and sustained (70-80 min) increase in urine flow rate and decrease in urinary sodium excretion; however, this free water diuresis is delayed in onset, commencing after arterial blood pressure and heart rate return toward control levels (i.e., approximately 30-min after i.c.v. peptide injection) Kapusta et al., 1997; . In comparison to these centrally evoked responses, i.v. bolus N/OFQ also produces a dose-dependent hypotension that occurs with bradycardia, and not a baroreflexevoked tachycardia (Bigoni et al., 1999; Champion et al., 1997a,b; Madeddu et al., 1999; Kapusta, 2000; Malinowska et al., 2000a Malinowska et al., , 2002 . However, these cardiovascular depressor depending on the in vitro or in vivo system studied . Despite their mixed pharmacological profiles these compounds continue to be classified and referred to (as they will be herein) as 'partial agonists' of the NOP receptor . Despite their unique and cellular/tissue/system-dependent pharmacological profile, it remains to be established how NOP receptor partial agonists affect cardiovascular and renal function in conscious rats as compared to the native ligand, N/OFQ. This is of particular interest since NOP receptors which are expressed in both central (brain, spinal cord) and peripheral tissues (vasculature, kidneys, heart, sympathetic and parasympathetic nerve terminals) (Mollereau and Mouledeous, et al., 2000; Malinowska et al., 2001; 2000b) 2000) , additional studies were performed to determine how the i.v. bolus pretreatment of conscious rats with these NOP receptor ligands modified the cardiovascular responses to a subsequent i.v. bolus N/OFQ challenge. used to position the cannula were 0.3 mm posterior to the bregma, 1.3 mm lateral to midline, and 4.5 mm below skull surface (Paxinos and Watson, 1986) . Verification of cannula position in the lateral ventricle was made by observation of cerebrospinal fluid flow from the implanted steel cannula after removal of the obturator or by observing injected dye in the lateral ventricle following completion of the study and subsequent postmortem brain section Kapusta et al., 1997 .
Materials and Methods

Subjects
On the day of the study, rats were anesthetized with sodium methohexital (75 mg/kg, i.p., and supplemented with 10 mg/kg, i.v. as needed; King Pharmaceuticals, Bristol, TN) and instrumented with chronic catheters in the left femoral artery and vein (PE-10 connected to PE-50; Becton Dickinson and Company; Sparks, MD) and urinary bladder (flanged PE-240; Becton
Dickinson and Company) for measurement of arterial blood pressure, administration of drugs/saline, and collection of urine, respectively. In certain studies, the rat (still anesthetized) was also implanted with a recording electrode (bipolar platinum wire; Cooner Wire Company, Chatsworth, CA) to a renal nerve branch to measure renal sympathetic nerve activity using standard techniques previously described Kapusta et al., 1997; .
Following surgical preparation, rats were placed in a rat holder (a chamber with Plexiglas ends connected by stainless steel rods) which permits forward and backward movement of the rat, allows for collection of urine, and when appropriate protects the renal nerve recording Heart rate and arterial pressure were continuously monitored and recorded on a Grass polygraph (model 7). Inc., Santa Barbara, CA). Integrated renal sympathetic nerve activity was expressed as microvolt-seconds per 1-sec intervals. For each 10-min experimental period, the values for integrated renal sympathetic nerve activity were sampled over the entire collection period and the numbers were averaged. Because of the limitations of comparing values for multifiber renal sympathetic nerve activity between animals, the data are expressed as the percent control with the control values for each animal taken as 100% .
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Results
We have previously reported that, in conscious rats, the i.c.v. microinjection of N/OFQ (5.5 nmol) produces bradycardia, hypotension, renal sympathoinhibition and water diuresis Kapusta et al., 1997; . As illustrated (Fig. 1) receptor partial agonists inhibited renal sympathetic nerve activity (data not shown). In the current studies HEX 1 and HEX 2 were each administered at a lower dose of 1.0 µg (1.0 nmol and 0.73 nmol, resp.) because preliminary findings revealed that the i.c.v. injection of 10-fold higher doses produced marked sedation. However, at these higher doses each NOP receptor ligand still produced cardiovascular, renal excretory and renal sympathetic nerve activity responses that were similar in pattern/direction as those elicited by i.c.v. N/OFQ (Kapusta et al., 1997; , 2000 . demonstrated that there were differences in time to onset and peak effects for N/OFQ (rapid onset and short duration) versus the other NOP receptor ligands (slow onset and long duration).
As such, cardiovascular data are presented as peak changes (mean ± SE) from control that occurred within the first 10 minutes immediately following i.v. bolus drug/saline injection ( Fig.   2A ) and the peak changes that were observed over the remaining 70-min protocol ( Fig. 2B ; time points 20-80 min). As shown in Fig. 2C , data for urine flow rate and urinary sodium excretion are the peak changes from pre-drug baseline control that occurred over the entire 80-min study produced an immediate and marked reduction in heart rate and mean arterial pressure ( Fig. 2A) with these responses returning to, and remaining at, pre-drug control levels approximately 10-min post injection (Fig. 2B) . In comparison to N/OFQ, the i.v. bolus injection of [F/G] (900 nmol/kg), HEX 1 (100 nmol/kg) or HEX 2 (100 nmol/kg) produced a substantially different cardiovascular response profile. For instance, each of these 3 NOP receptor ligands failed to produce an immediate and marked bradycardia or hypotension following i.v. bolus injection ( Fig. 2A) . In fact, at this dose (100 nmol/kg, i.v.) these ligands did not significantly alter baseline cardiovascular function over the first 10-min following administration. However, by approximately 10-15 min following injection each of these ligands produced a subtle (but statistically significant) hypotensive response (ranging from 10 to 20 mmHg) that persisted for 60-70 min ( Fig. 2B ; periods 10-80 min; see Fig. 3 for time course data for HEX 1). Fig. 2C demonstrates that N/OFQ and the purported NOP receptor partial agonists also differed in their ability to affect urine output, but not urinary sodium excretion. Thus, i.v. N/OFQ failed to increase urine flow rate over the entire experimental period (80 min) at this (100 nmol/kg) or other doses (10, 30 or 300 nmol/kg, data not shown) tested. In contrast, at an equivalent dose (100 nmol/kg) i.v. bolus injection of [F/G], HEX 1 and HEX 2 each produced a significant diuresis over the 80-min study (Fig. 2C , and see Fig. 3 for time course data for HEX 1). The peak increases in urine flow rate and urinary sodium produced by [F/G] and HEX 2 occurred 30-min after injection, whereas peak renal excretory responses to HEX 1 were evident by 40-min.
The renal excretory responses produced by [F/G] and HEX 2 were fully recovered by 50-min (data not shown) after drug injection, whereas changes elicited by HEX 1 returned to control levels by 60-min (Fig 3) . Note that the changes in renal excretory function depicted in Fig. 2C do However, there is now considerable evidence that each of these ligands can each behave as pure antagonists Bigoni et al., 1999; Madeddu et al., 1999 , Berger et al., 2000 Malinowska et al., 2000b) , partial agonists (Dooley et al., 1997; Bigoni et al., 1999; Berger et al., This article has not been copyedited and formatted. The final version may differ from this version. 2000; Calo' et al., 2000) or full agonists (Butour et al., 1998; Berger et al., 2000; Malinowska et al., 2000a; Olszewski et al., 2000) across different in vitro and in vivo systems (see Calo' et al, 2000 for review) . The results of the present studies extend these observations and clearly demonstrate that these same NOP receptor ligands can display mixed pharmacological behavior from full/partial agonist to antagonist activity within a given biological system, in this case involving processes regulating cardiovascular and renal function in vivo.
As we previously reported for [F/G] , the i.c.v. injection of all 3 NOP receptor ligands in conscious rats produced cardiovascular depressor and water diuretic responses that were similar in pattern and magnitude to those elicited by N/OFQ, thus behaving as full agonists. Although not tested, it is likely that these NOP receptor ligands acted centrally to affect cardiovascular and renal function in a manner similar to N/OFQ through modulation of central neural (sympathetic inhibitory and parasympathetic stimulatory) outflow (Giuliani et al., 1997; Kapusta et al., 2002 Shirasaka et al., 1999 and inhibition of ADH release (Kapusta, 2000; Kakiya et al., 2000) . In contrast to their responses in the brain, when
[F/G], HEX 1 and HEX 2 were administered into the periphery as an i.v. bolus injection these compounds did not alter heart rate and only gradually and slightly reduced mean arterial pressure. These observations are of interest considering that N/OFQ (30 or 100 nmol/kg) characteristically produces an immediate and marked bradycardia and hypotension following i.v.
bolus injection in conscious or anesthetized rats (Bigoni et al., 1999; Champion et al., 1997a,b; Madeddu et al., 1999; Kapusta, 2000; Malinowska et al., 2000a Malinowska et al., , 2002 . However, as partial agonists it might be expected that these ligands are required to bind to and activate more receptors to elicit an equal response. This possibility was excluded though, since in dose- 100 or 300 nmol/kg) tested did not itself affect urine flow rate. Of interest though, in previous studies we showed that N/OFQ is effective in producing a water diuresis when administered as a continuous i.v. infusion (Kapusta et al., 1997; Kapusta, 2000) . Moreover, during i.v. infusion N/OFQ (low or high dose) does not elicit any marked cardiovascular responses and instead produces only a subtle reduction in mean arterial pressure with no change in heart rate (Kapusta et al., 1997; Kapusta, 2000) , these being cardiovascular responses similar to those elicited by i.v.
bolus injection of NOP receptor partial agonists (present study). While the mechanisms have yet to be explored, it is apparent that by altering the method of i.v. drug administration (infusion versus bolus injection) the pattern of cardiovascular and renal excretory responses produced by N/OFQ can change and can highly mimic that elicited by the i.v. bolus injection of the NOP receptor partial agonists.
At present, the mechanisms by which purported NOP receptor partial agonists produce functionally selective effects on cardiovascular and renal function remain unknown. Different subtypes of NOP receptors in central versus peripheral tissues have been speculated, but not reported to exist. Alternatively, the NOP receptor density and stimulus/response coupling efficiency in various tissues (e.g., potentially high in the CNS and low in peripheral tissues) may influence the degree of agonism of the three low efficacy agonists (i.e., partial agonists) used in this study (Berger et al., 2000; McDonald et al., 2003) . This premise is supported by studies which have used an ecdysone inducible expression system showing that partial agonist behavior of a ligand is dependent upon the level of NOP receptor expression (McDonald et al., 2003) .
Together, our data strongly indicates that there exists agonist-specific regulation of the NOP receptor. Structure-activity studies have suggested that the mode of binding between the hexapeptide HEX 1 and the NOP receptor is different than that between N/OFQ and NOP (Kawano et al., 2002) . In fact, using photo-affinity labeling, Bes and Meunier (2003) have identified a hexapeptide binding site within the NOP receptor that is physically remote and distinct from the region in which N/OFQ binds. As suggested by these investigators, it is likely that the ability of the hexapeptides and N/OFQ to interact with the NOP receptor in different ways (i.e., affects on G-protein coupling and second messenger pathways) is consistent with their distinct pharmacological activities (Bes and Meunier, 2003) . (Fig. 4A , 900 nmol/kg; n=6), HEX 1 (Fig. 4B , 100 nmol/kg; n=8) or HEX 2 ( Fig. 4B , 100 nmol/kg; n=6). MAP, mean arterial pressure; HR, heart rate. See Fig. 1 Basal control values for each parameter prior to vehicle/drug pretreatment were not significantly different between groups.
